Ironwood Pharma (IRWD) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update
February 21, 2017 4:01 PM ESTIronwood revenue in 2016 was $274 million, an 83% increase over 2015, driven primarily by 2016 LINZESS® (linaclotide) U.S. net sales of $626 million and expansion of LINZESS commercial margin to 58%
Key pipeline milestones in linaclotide colonic release, vascular/fibrotic diseases, and uncontrolled gout programs
Multiple value-creating catalysts expected in 2017, including 2 commercial launches, 4 mid-stage clinical data readouts and 4 mid- to late-stage trial initiations
R&D Day on Thursday, March 9th to provide detailed discussion of Ironwoods strategy and execution
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
